Our commitment
Since 2007, we have worked to develop lifesaving and life altering therapies through pioneering research and innovation. This endeavour clearly showcases our commitment to those living with rare conditions. However, our work also goes beyond the individual. From big picture issues to day-to-day ways of working, we strive to live up to the high ethical standards we set ourselves and be a force for good both for individuals and society as a whole.
Our commitment to patients
At Hansa Biopharma, we are fully committed to developing innovative treatments to help patients with rare immunologic conditions live longer and healthier lives. With our work, we want to contribute to overcome the immunological barriers that might prevent these patients from accessing treatment, therefore helping fulfil their unmet needs.
Through meaningful interactions with advocacy groups, we want to help patients be heard, give them an opportunity to share their stories, and gain further knowledge and awareness from their experience. We believe it is crucial to understand the journey a person may face, from diagnosis to treatment success or failure and how lives can be affected along the way. Every patient is unique and by understanding and valuing the uniqueness of their stories and perspectives, we will do our part in achieving better treatment outcomes for all.
Our commitment to the medical community
Advances in scientific understanding and research are central drivers of progress within the medical community and are also at the heart of Hansa’s business. Our participation in ongoing scientific exchange with the medical community is therefore one of our highest priorities; whether through the publication of our research in peer-reviewed journals, the presentation of our data at scientific congresses, or the sponsorship and support given to healthcare professional organizations.
Currently, we are working to educate transplantation centers on the value of our products and to help identify which patients would benefit the most from them. As our treatment portfolio expands, we will continue to build relationships with healthcare providers and work to secure access where possible to maximize the impact of our therapies.
We are also proud to have established a unique collaboration with the European Society of Transplantation (ESOT) where we sponsor a workstream on desensitization. The goal of this initiative is to develop a more standardized, and consensus-driven approach to the desensitization of transplant patients in Europe, thereby broadening the horizons for highly sensitized patients, who would otherwise struggle to find a match.
Access to medicines
Providing access to medicines for those who need them is not down to a single actor, but a shared responsibility. At Hansa, we aim to support initiatives that promote access to our therapies for every patient who needs them. We do this by collaborating with patient groups and supporting educational programs.
Acting responsibly
Integrity is more than just a watchword at Hansa. It defines who we are. From big picture issues to day-to-day ways of working, we strive to live up to the high ethical standards we set ourselves. To meet these high standards, we have developed guidelines and a rigorous code of conduct to span the breadth of the work we do, and provide guidance to our employees on how to do the right thing. These guidelines apply to all the work we do and cover important topics such as environmental sustainability, diversity and inclusion, and selecting the best third-party suppliers and partners. Our corporate governance page contains more information on our company policies.
Corporate governance
When selecting suppliers and entering new partnerships, we commit to new responsibilities. We therefore choose our partners carefully and provide guidance on our expectations via our supplier code. We also encourage our business partners to be proactive in their commitments and support the 17 Sustainable Development Goals laid out by the United Nations.
Hansa is proud to be part of American Society of Transplantation’s Living Donor Circle of Excellence, which aims to eliminate the financial costs of living organ donation by recognizing companies who support living donation through providing lost wages. Read more about this initiative here.
